Quality control of residual solvent content in polymeric microparticles

Journal of Microencapsulation

Volumn 32, Issue 2, 2015, Pages 107-122

  Dixit, Kalpana ^a   Athawale, Rajani B ^a   Singh, Sarabjit ^b  

^a SNDT WOMEN S UNIVERSITY   (India)

^b Panacea Biotec Ltd   (India)

Author keywords

Microencapsulation; Phase separation coacervation; Regulatory perspective

Indexed keywords

NANOPARTICLE; ORGANIC SOLVENT; POLYMER; SOLVENT;

ARTICLE; COACERVATION; DRUG INDUSTRY; FREEZE DRYING; GLASS TRANSITION TEMPERATURE; MICROENCAPSULATION; PHASE SEPARATION; PHYSICAL CHEMISTRY; POLYMERIZATION; PRACTICE GUIDELINE; QUALITY CONTROL; VACUUM; CHEMISTRY; HUMAN; PROCEDURES; STANDARDS; SYNTHESIS;

DRUG INDUSTRY; HUMANS; POLYMERS; QUALITY CONTROL; SOLVENTS;

EID: 84931029917     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2014.995730     Document Type: Article

References (68)

1. Aftabroushad S, Doelker E. Factors influencing the entrapment of a water soluble model drug into injectable microparticles prepared using solvent evaporation and phase separation techniques. Eur J Pharm Biopharm, 1994;40:237-42.
2. Bergsma JE. Late degradation tissue response to poly(L-lactide) bone plates and screws. Biomaterials, 1995;16(1):25-31.
3. B'Hymer C. Residual solvent testing: A review of gas chromatographic and alternative techniques. Pharm Res, 2003;20:337-43.
4. Bouissou C, Rouse JJ, Price R, Van der Walle CF. The influence of surfactant on PLGA microsphere glass transition and water sorption: Remodeling the surface morphology to attenuate the burst release. Pharm Res, 2006;23:1295-305.
5. Camarasu C. Unknown residual solvents-Identification in drug products by headspace solid phase microextraction gas chromatography and mass spectroscopy. Chromatographia, 2002;56:S131-5.
6. Changqin H, Ying L. 2011. Quality control in pharmaceuticals: Residual solvents testing and analysis. In: Akyar I, ed. Wide spectra of quality control, InTech, 183-210. [Online] Available at: http:// www.intechopen.com/books/wide-spectra-of-quality-control/qualitycontrol-in-pharmaceuticals-residualsolvents-testing-and-analysis. Accessed 1 March 2014.
7. Choi SW, Kwon HY, Kim WS, Kim JH. Thermodynamic parameters on poly(D, L-lactide-co-glycolide) particle size in emulsification-diffusion process. Colloids Surf A, 2002;201:283-9.
8. Davies OR, Lewis AL, Whitaker MJ, Tai H, Shakesheff KM, Howdle SM. Applications of supercritical CO2 in the fabrication of polymer systems for drug delivery and tissue engineering. Adv Drug Delivery Rev, 2008;60:373-87.
9. Dijkhuizen-Radersma RV, Hesseling SC, Kaim PE, Groot KD, Bezemer JM. Biocompatibility and degradation of poly(ether-ester) microspheres: In vitro and in vivo evaluation. Biomaterials, 2002; 23(24):4719-29.
10. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: New estimates of drug development costs. J Health Econ, 2003; 22(2):151-85.
11. Dwivedi AM. Residual solvent analysis in pharmaceuticals. Pharm Tech, 2002;2002:42-6.
12. Falk RF, Randolph TW. Process variable implications for residual solvent removal and polymer morphology in the formation of gentamycinloaded poly(L-lactide) microparticles. Pharm Res, 1998;15(8):1233-7.
13. Gentile P, Chiono V, Carmagnola I, Hatton PV. An overview of poly(lactic-co-glycolic) acid (PLGA)-based biomaterials for bone tissue engineering. Int J Mol Sci, 2014;15:3640-59.
14. Heller J. Biodegradable polymers in controlled drug delivery. Crit Rev Ther Drug Carrier Syst, 1984;1(1):39-90.
15. Heller J. Controlled drug release from poly(ortho esters)-A surface eroding polymer. J Control Release, 1985;2:167-77.
16. Heller J. Controlled release of biologically active compounds from bioerodible polymers. Biomaterials, 1980;1:51-7.
17. Houchin ML, Topp EM. Physical properties of PLGA films during polymer degradation. J Appl Polym Sci, 2009;114:2848-54.
18. Jain RA. The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices. Biomaterials, 2000;21:2475-90.
19. Jalil R, Nixon JR. Biodegradable poly(lactic acid) and poly(lactide-coglycolide) microparticles: Problems associated with preparative techniques and release properties. J Microencapsul, 1990;7:297-325.
20. Jeyanthi R, Thanoo BC, Metha RC, Deluca PP. Effect of solvent removal technique on the matrix characterstics of polylactide/glycolide microspheres for peptide delivery. J Control Release, 1996;38(2-3):235-44.
21. Komen J, Groennendaal JW. 1991. Process of microencapsulation. US Patent No. 5066436.
22. Koushik K, Kompella UB. Preparation of large porous deslorelin-PLGA microparticles with reduced residual solvent and cellular uptake using a supercritical carbon dioxide process. Pharma Res, 2004; 21(3):524-35.
23. Kushwaha P. Organic volatile impurities: A regulatory overview. Pharma Times, 2012;44(5):25-30.
24. Lawter JR, Lanzilotti MG. 1992. Hardening agent for phase separation microencapsulation. European Patent Application, EP 0292710 A2.
25. Lewis DH, Sherman JD. 1989. Low residual solvent microspheres and microencapsulation process. PCT Patent No. WO 1989/003678.
26. Lewis DH. 1990. Controlled release of bioactive agents from lactide/ glycolide polymers. In: Chasin M, Langer R, eds. Biodegradable polymers as drug delivery systems. New York: Marcel Dekker, pp. 1-41.
27. Lu LC, Peter SJ, Lyman MD, Lai HL, Leite SM, Tamada JA, Vacanti JP, Langer R, Mikos AG. In vitro degradation of porous poly(L-lactic acid) foams. Biomaterials, 2000;21:1595-605.
28. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers (Basel), 2011;3:1377-97.
29. Michulec M, Wardenki W. Development of headspace solid-phase microextraction-gas chromatography method for the determination of solvent residues in edible oils and pharmaceuticals. J Chromatogr, 2005;1071: 119-24.
30. Middleton J. 2012. Tailoring of poly(lactide-co-glycolide) to control their properties for medical device and pharmaceutical. [Online] Available at: http://www.fda.gov/downloads/MedicalDevices/NewsEvents/Work shopsConferences/UCM335606.pdf. Accessed 3 August 2014.
31. Mullard A. 2011. FDA drug approvals. Nat Rev Drug Discov, 2012;1: 91-4.
32. Murakami H, Kobayashi M, Takeuchi H, Kawashima Y. Preparation of poly(DL-lactide-co-glycolide) nanoparticles by modified spontaneous emulsification solvent diffusion method. Int J Pharm, 1999;187: 143-52.
33. Nakano M, Ithoh M, Juni K, Sekikawa H, Arita T. Sustained urinary excretion of sulfamethizole following oral administration of enteric coated microcapsules in humans. Int J Pharm, 1980;4(4):291-8.
34. Nerlich B, Gustafsson J, Mank R, Horig J, Kochling W. 1993. Process for microencapsulation of water soluble drugs. Deutsche Patentschrift No. DE 4223169 C1.
35. Nihant N, Stassen S, Grandfils C, Jerome R, Teyssie Ph, Goffinet G. Microencapsulation by coacervation of poly(lactide-co-glycolide). III Characterization of the final microspheres. Polym Int, 1994;34:289-99.
36. Nihant N, Stassen S, Grandfils C, Jerome R, Teyssie Ph. Microencapsulation by coacervation of poly(lactide-co-glycolide). II Encapsulation of a dispersed aqueous phase. Polym Int, 1993;32: 171-6.
37. Orsolini P, Mauvernay RY, Deghengi R. 1987. Microencapsulation by phase separation of water soluble medicaments. US Patent No. 4673595.
38. Orsolini P, Mauvernay RY, Deghengi R. 1986. Process for microencapsulation of water soluble drugs by phase separation. Deutsche Offenlegungsschrift Application, DE 3536902 A1.
39. Otero R, Carrera G. Static headspace gas chromatographic method for quantitative determination of residual solvents in pharmaceutical drug substances according to European Pharmacopoeia requirements. J Chromatogr A, 2004;1057:193-201.
40. Perkins B, Pattanaik A. 2012. Emulsion method for preparing low residual solvent microparticles. US Patent Application, US 2012/ 0083444 A1.
41. Peterson H, Lambert O, Loeffler R, Ausborn M, Bonny J-D. 2007. Organic compounds. US Patent Application, US 2007/0122485 A1.
42. PRNewswire. 2011. Parenteral depots offer $8 billion of reformulation opportunities and a strong competitive edge in crowded pharmaceutical space. [Online] Available at: http://www.prnewswire.com/newsreleases/ parenteral-depots-offer-8-billion-of-reformulation-opportunities-and-a-strong-competitive-edge-in-crowded-pharmaceutical-space-116156554.html. Accessed 17 March 2014.
43. Quintanar-Guerrero D, Fessi H, Allemann E, Doelkar E. Influence of stabilizing agents and preparative variables on the formation of poly(D, L-lactic acid) nanoparticles by an emulsification-diffusion technique. Int J Pharm, 1996;143:133-41.
44. Raiche AT, Perkins BH. 2013. Method for removing residual organic solvent from microparticles. European Patent Application, EP 2621473 A2.
45. Ramstack JM. 2005. Method for preparing microparticles using liquid-liquid extraction. US Patent No. 6884372 B2.
46. Rasal RM, Hirt DE. Toughness decrease of PLA-PHBHHx blend films upon surface confined photopolymerization. J Biomed Mater Res A, 2009;88A(4):1079-86.
47. Rickey ME, Ramstack JM, Kumar R. 2009. Residual solvent extraction method and microparticles produced thereby. US Patent No. 7524530 B2.
48. Rickey ME, Ramstack M, Lewis DH, Mesens J. 1998. Preparation of extended shelf-life biodegradable, biocompatible microparticles containing a biologically active agent. US Patent No. 5792477.
49. Rickey ME, Ramstack M, Lewis DH. 1999. Preparation of biodegradable, biocompatible microparticles containing a biologically active agent. US Patent No. 5916598.
50. Ruhe PQ, Hedberg EL, Padron NT, Spauwen PH, Jansen JA, Mikos AG. rhBMP-2 release from injectable poly (DL-lactic-co-glycolic acid)/ calcium-phosphate cement composites. J Bone Jt Surg, 2003;85:75-81.
51. Saez V, Hernandez JR, Peniche C. Microsphere as delivery system for the controlled release of peptide and proteins. Biotechnol Appl, 2007;24: 108-16.
52. Song KC, Lee HS, Choung II Y, Cho KI, Ahn Y, Choi EJ. The effect of type of organic phase solvents on the particle size of poly(D,L-lactideco-glycolide) nanoparticles. Colloids Surf A Physicochem Eng Asp, 2006;276:162-7.
53. Tamber H, Johansen P, Merkel HP, Gander B. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv Drug Delivery Rev, 2005;57:357-76.
54. The United States Pharmacopeia Convention. 2013. General chapters/ chemical tests/54674 residual solvents. In: The United States Pharmacopeial Convention, ed. US Pharmacopeia 36 National Formulary 31, Volume 1. Maryland: United Book Press, pp. 195-207.
55. Thioune O, Fessi H, Devissaguet JP, Puisieux F. Preparation of pseudolatex by nanoprecipitation: Influence of the solvent nature on intrinsic viscosity and interaction constant. Int J Pharm, 1997;146: 233-8.
56. Thomasin C, Johensen P, Alder R, Bemsel R, Hottinger G, Altorfer H, Wright AD, Wehrli E, Merkel HP, Gander B. A contribution to overcoming the problem of residual solvents in biodegradable microspheres prepared by coacervation. Eur J Pharm Biopharm, 1996;42: 16-24.
57. Thomasin C, Merkel HP, Gander BA. Physico-chemical parameters governing protein microencapsulation into biodegradable polyesters by coacervation. Int J Pharm, 1997;147:173-86.
58. Thomasin C, Merkle HP, Gander B. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 2. Parameters determining microsphere formation. J Pharm Sci, 1998b; 87(3):269-75.
59. Thomasin C, Nam-Tran H, Merkel HP, Gander B. Drug microencapsulation by PLA/PLGA coacervation in the light of thermodynamics. 1. Overview and theoretical considerations. J Pharm Sci, 1998a; 87(3):259-68.
60. Tice TR, Tabbi ES. 1991. Parenteral drug delivery: Injectables. In: Kydonieus A, ed. Treatise on controlled drug delivery: Fundamentals, optimization, applications. New York: Marcel Dekker, pp. 315-39.
61. Torza S, Mason SG. Three-phase interactions in shear and electrical fields. J Colloid Interface Sci, 1970;33(1):67-83.
62. Van Krevelen DW. 1990. Properties of polymers, 3rd edn. Amsterdam: Elsevier, pp. 189-225, 287-320.
63. Vilos C, Velasquez LA. Therapeutic strategies based on polymeric microparticles. J Biomed Biotechnol, 2012;2012:1-9.
64. Wang HT, Palmer H, Linhardt RJ, Flanagan DR, Schmitt E. Degradation of poly(ester) microspheres. Biomaterials, 1990;11(9):679-68.
65. Witschi C, Doelker E. Residual solvents in pharmaceutical products: Acceptable limits, influence on physicochemical properties, analytical methods and documented values. Eur J Pharm Biopharm, 1997; 43(3):215-42.
66. Wu XS. 1995a. Preparation, characterization and drug delivery applications of microspheres based on biodegradable lactic/glycolic acid polymers. In: Wise DL, Trantolo DJ, Altobelli DE, Yaszernski MJ Gresser JD, Schwartz ER, eds. Encyclopedic handbook of biomaterials and bioengineering. New York: Marcel Dekker, pp. 1151-250.
67. Wu XS. 1995b. Synthesis and properties of biodegradable lactic/glycolic acid polymers. In: Wise DL, Trantolo DJ, Altobelli DE, Yaszernski MJ, Gresser JD, Schwartz ER, eds. Encyclopedic handbook of biomaterials and bioengineering. New York: Marcel Dekker, pp. 1015-54.
68. Wu XS, Wang N. Synthesis, characterization, biodegradation, and drug delivery application of biodegradable lactic/glycolic acid polymers. Part II: Biodegradation. J Biomater Sci Polym, 2001;12:21-34.